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Abstract A recent discussion meeting convened by the Medicines for Malaria Venture examined how best to
manage the discovery and preclinical pipeline to achieve novel combination therapies which would
address the key clinical needs in malaria. It became clear that dose optimisation of components within
combination therapy was a key issue in achieving antimalarial efﬁcacy and for preserving that efﬁcacy
against parasite resistance emergence. This paper outlines some of the speciﬁc issues in malaria that
cause dose-ranging and dose-optimisation studies to be particularly challenging and discusses the
potential of factorial study design to address such challenges.
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Introduction
Artemisinin revolutionised antimalarial therapy and fore-
stalled a catastrophe. By 2001, Plasmodium falciparum
resistance to conventional antimalarials had left many
countries with no effective, affordable treatment (Roll Back
Malaria 2001; World Health Organization 2010). Atten-
dant to this was an increase in mortality, morbidity, and the
frequency and severity of malaria epidemics (Roll Back
Malaria 2001). The speed and extent of parasite killing
with artemisinin is unprecedented. However, a short half-
life requires combination with a longer-acting partner to
achieve sustained cure with a 3-day treatment schedule
(Alin et al. 1996; Giao et al. 2001). Today, artemisinin-
based combination therapy (ACT) is highly efﬁcacious with
day-28 cure rates generally exceeding 95% (adjusted for
reinfection with polymerase chain reaction genotyping),
and costs less than $1 per adult treatment (World Health
Organization 2010). However, ACT efﬁcacy will not last
forever; P. falciparum resistance is already emerging (Noedl
et al. 2008; White 2010; World Health Organization 2011).
The spectre of untreatable P. falciparum rejuvenated
antimalarial drug research (Roll Back Malaria 2001). It
was realised that ACT was not the ‘ultimate’ antimalarial,
resistance would develop, and post-artemisinin alternatives
were needed. Consequently, we now have new compounds,
many with novel mechanisms of action, moving from
discovery into development.
Treatment of acute P. falciparum infection is not the
only clinical objective. There are other targets that could
potentially beneﬁt from novel antimalarial combinations.
• Plasmodium vivax acute therapy: chloroquine resis-
tance is an issue in some regions (Baird 2011).
• Treatment of P. vivax hypnozoites, the cause of
clinical relapse (Galappaththy et al. 2007).
• Drugs that interrupt malaria transmission: a key
component of malaria elimination efforts (The mal-
ERA Consultative Group on Drugs 2011).
In this revival of antimalarial drug development, safety
and efﬁcacy remain the dominant objectives. However, the
need to protect new agents against the development of
parasite resistance is also recognised. Thus, new antimal-
arials will be used in combinations with components of
differing pharmacodynamics and⁄or pharmacokinetics.
For ease of use, and to avoid their use as monotherapy,
these combinations will be presented as ﬁxed-dose formu-
lations. Critically, doses must be optimised for use in
children, whose limited immunity places them most at risk
of mortality and adverse outcome (Carneiro et al. 2010).
Formulations that increase acceptability in this target
group should be a drug development priority (e.g. granules,
dispersible tablets). But how do we optimize new antima-
larial combinations and doses for different indications and
patient populations?
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Therearenoapprovedregulatoryguidelinesforantimalarial
combination therapy development, but some guidance
documents are relevant, such as those for ﬁxed-dose com-
binations. Although experience was gained with ACT, this
may not be adequate for developing the antimalarials of the
future(Box 1):ACTwasneededquickly,initialdose-ﬁnding
was empiric and formal dose-ﬁnding studies were limited.
In HIV drug development, in vitro activity and partic-
ularly the drug resistance proﬁle greatly inform the
pathway to choosing potential drug regimens used in
clinical therapy (Zhuang & Li 2011). In tuberculosis,
murine models are valuable in demonstrating the efﬁcacy
of different agents in combination (Apt & Kramnik 2009).
In malaria, however, there are no validated methods that
support the choice of combination partners or their relative
doses (Bell 2005; Langhorne et al. 2011). In vitro studies
are useful for determining drug activity by various
measures, and although outcomes depend on the parasite
strain and the stage mix of the parasite population, such
studies are straightforward and inexpensive to perform
(Noedl et al. 2003; Bell 2005). Drug interactions can be
investigated in vitro using isobologram experiments (Co
et al. 2009), though the clinical relevance of mild synergy
or antagonism is not often clear (Bell 2005). Rodent
models can also provide useful information, and the
development and improvement of the humanised mouse
model is a potentially signiﬁcant advance (Arnold et al.
2011). However, despite an array of pre-clinical tools in
malaria, when we look at these experiments with a view to
designing a clinical development program there are still
enormous uncertainties. Also, it is becoming clear that
established tests may not be appropriate for new agents or
new clinical objectives, such as transmission blocking, and
new validated methods must be developed (Wein et al.
2010; The malERA Consultative Group on Drugs 2011).
Clinical proof-of-concept studies provide useful infor-
mation on drug efﬁcacy as monotherapy. However, these
data could be misleading if the to the dose–response of the
individual components is different in combination. Human
pharmacokinetic studies are a regulatory requirement, and
can be designed to provide useful background information
to inform dose selection in combination. Such studies
would need to be performed in healthy controls and
patients with malaria. However, although pharmacoki-
netic⁄pharmacodynamic data can be used to justify dose
choices to regulatory authorities, dose-ranging studies will
provide the main evidence for the dosing rationale.
Unfortunately, until the combination can be tested in
malaria patients, choosing the doses for dose-ranging
studies is a best estimate. We are, therefore, left with
having to choose the component doses for new combina-
tions at a late stage in clinical development.
Factorial design: a perfect ﬁt?
Factorial study designs offer a potential solution. A
factorial design compares two or more components
simultaneously. Such studies are well established in
engineering applications (Myers et al. 2009). In drug
development, they are used for animal models, but for
clinical dose-ﬁnding their application has been limited
mainly to hypertension (Pool et al. 1997). There is a
precedent for using simple two-by-two factorial designs in
studies of malaria combination therapy (Mulenga et al.
2006; Wootton et al. 2008). These studies compared
combinations of two drugs each given at two different
Box 1 Challenges for novel antimalarial combination therapy drug development compared with the development of
artemisinin-based combination therapy (ACT).
Model term ACT Novel combination therapies
Combination
components
Artemisinin plus an existing drug used previously
as monotherapy
One or more combination partners are new chemical
entities
Regulatory
procedure
Safety and efﬁcacy evaluated for the combination
therapy
Stringent process. Proof of concept required for
monotherapy and combination therapy. Safety and
efﬁcacy evaluated for the combination therapy
Clinical data Initial evidence mostly from the Thailand border
areas in adult populations
Clinical data required from multiple centres in Asia,
Africa and South America. Extensive clinical data
from children required
Formulation Loose or ﬁxed combinations Fixed combinations only
Paediatric
formulation
Crushed adult formulation tablets used for paediatric
administration. Paediatric formulations developed
retrospectively in some cases. One dose ﬁts all
Initial development of a paediatric formulation that
can also be used in adults. Separate evaluation of dose
and duration in children and adults
Dose ﬁnding Empiric, based on data from monotherapy studies Rational and optimised within combination therapy
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designed decision algorithm. However, these studies were
not designed for dose-ﬁnding. To our knowledge, facto-
rial design has not been used for dose-ﬁnding in malaria.
However, it is only really with the availability of novel
antimalarials and the shift to combination therapy that
such a need has emerged.
Factorial study designs use a statistical model to enable
interpolation of dose–response information. A quadratic
model is the one most commonly used for clinical trials
(Pool et al. 1997). This model allows for non-linearity of
the dose–response. This may only be evident when the
drugs are used in combination. The model is used to
construct a dose–response surface that allows estimation of
the optimal dose within the matrix, i.e. the model can
suggest the ‘ideal’ dose even if that dose was not actually
tested (see idealised example in Box 2). However, note that
in clinical malaria, a placebo⁄placebo comparison would
not be appropriate because of the risk of serious adverse
outcomes. In all cases, a minimally effective dose would
need to be established before designing the dosing matrix.
Because the model allows data to be compared across the
whole matrix rather than pairwise, sample sizes for each
data collection point can be quite low. This can reduce
development timelines but must be balanced against the
need for safety data, so sample sizes may need to be
increased to provide an adequate safety database.
Factorial design has a number of advantages.
• Because monotherapy and combination therapy can
be tested simultaneously, the contribution of each
component and their interaction can be investigated in
one experiment.
• The cost of a factorial study is potentially less than
dose ranging on individual components followed by
studies on the combination as only certain compo-
nent–dose combinations are necessary to construct the
dose–response surface.
• As the model includes dose regimens outside those
that were actually tested, there is some ﬂexibility
should the drugs interact in an unexpected manner,
for example, with signiﬁcant synergy, antagonism or
even both in different regions of the matrix.
• Combinations including agents with very different
pharmacokinetic⁄pharmacodynamic proﬁles may be
particularly suited to this design, as their interaction is
difﬁcult to predict and can be compared across a wide
range of doses.
• Calculating the dose–response surface can limit
unnecessary exposure to ineffective or potentially
toxic drug levels. For example, as for any dose-
ranging study, there is a lower dose limit at which the
experiment must be interrupted to administer rescue
Box 2 Idealised example of a factorial study design
(provided by LK).
Sample size grid
Data are analysed across the whole grid, rather than
pair-wise. This means that only small sample sizes are
required. Note that the largest sample sizes are in the
extremes of the grid (for a quadratic model).
Drug 1
Drug 2 Placebo Dose 1 Dose 2 Dose 3 Dose 4
Placebo 30* 10 10 10 44
Dose 1 10 10 10 10 10
Dose 2 10 10 10 10 10
Dose 3 35 10 10 10 49
*NB: A placebo⁄placebo arm would not be ethical in clinical malaria.
Responses
Response data are obtained for each dose combination.
In this example, high values indicate a good response.
Drug 1
Drug 2 Placebo Dose 1 Dose 2 Dose 3 Dose 4
Placebo 0 0.08 0.15 0.24 0.29
Dose 1 0.1 0.18 0.24 0.34 0.38
Dose 2 0.15 0.23 0.29 0.39 0.43
Dose 3 0.11 0.18 0.25 0.34 0.37
Dose–response plot
Based on the observed data obtained in the study, the
combination of Drug 1, dose 4 and Drug 2, dose 2 would
be chosen. However, as can be seen onthe dose–response
surface plot below, the model predicts a slightly better
response, indicated by arrow at a dose that was not
studied in the trial.
Note that for simplicity the data and output are pre-
sented purely as mean values. Conﬁdence intervals are
very important to show the level of precision obtained
for these means and for real study output these would be
presented and even drawn on the plot.
M
o
d
e
l
l
e
d
 
o
u
t
c
o
m
e
0.0
Dose 4
DRUG 1
Dose 3
0.1
0.2
0.3
0.4
0.5
0.6
Dose 2
Dose 1
Dose 1
Dose 2
Dose 3
0
0
DRUG 2
Maximum response of doses
tested experimentally Maximum response 
predicted by model
Tropical Medicine and International Health volume 17 no 4 pp 409–413 april 2012
S. Duparc et al. Optimal dose for new malaria therapy
ª 2012 Blackwell Publishing Ltd 411therapy. Malaria can be deadly and patients cannot be
exposed to sub-therapeutic doses for any signiﬁcant
time. However, factorial design offers the possibility
to construct a dose–response surface in which the
minimum of patients are exposed to sub-therapeutic
doses. This should be at the heart of the design scheme
for antimalarial combination therapies.
Balanced against these advantages, the statistical and
practical input to a factorial dose-ﬁnding study is consid-
erable. The up-front design work, including sensitivity
analysis and simulations, requires specialised statistical
resources. Also, managing a trial with multiple drug
combinations at different doses presents practical issues.
Dose choice will also be inﬂuenced by the possibility that
highly effective antimalarials may have high efﬁcacy over a
large range of doses.
Another key difﬁculty is regarding outcomes. Antimal-
arials that are highly effective in rapidly reducing parasite
burden may show little additional contribution in
combination therapy based on clinical outcomes at day
28. For antimalarials with long half-lives, recrudescence
may not be evident for longer follow-up periods. For
rapidly acting blood schizontocidal antimalarials,
evaluating parasite clearance rate versus an artemisinin
monotherapy arm (with a subsequent long-acting rescue
therapy) may be possible, but requires clinical validation.
For combinations of antimalarials with diverse pharma-
codynamic⁄pharmacokinetic proﬁles, it may be necessary
to evaluate more than one outcome. This further com-
plicates statistical modelling for factorial designs. In
vulnerable patients, such as children, it is critically
important to have information on the minimally effective
doses before including such patients in trials that can then
be designed to optimise dose–response above this thresh-
old. Consequently, further data may need to be collected
from studies in adults with malaria, or by using alterna-
tive endpoints, such as human challenge experiments or
clearance of asymptomatic parasitaemia before
proceeding.
The availability of novel antimalarial candidates pro-
vides an opportunity to test new approaches to dose
optimisation for combination therapy, such as factorial
design. Deﬁning appropriate outcomes to adequately
differentiate between drug and dose combinations targeted
at speciﬁc clinical objectives will be a key consideration.
However, as a pioneering methodology in antimalarial
drug development, factorial design should be considered on
a case-by-case basis as a potential tool to optimise the
efﬁcacy, safety and longevity of future antimalarial com-
bination therapies.
Acknowledgements
An initial draft of this paper was written by Naomi
Richardson of Magenta Communications Ltd who was
funded by the Medicines for Malaria Venture (MMV) and
who also developed the minutes of the discussion meeting
from which the paper was derived – Development of
combination therapies for the treatment of uncomplicated
P. falciparum malaria. We acknowledge input from the
following participants at the discussion meeting: Pascal
Ringwald, World Health Organization – Global Malaria
Programme; Renata Albrecht, US Food and Drug Admin-
istration; Eric Pelfrene, European Medicines Agency; Mair
Powell, Medicines and Healthcare Products Regulatory
Agency; Ann Ginsberg, Aeras Global TB Vaccine Foun-
dation (formerly TB Alliance at the time of the meeting);
John Pottage, ViiV Healthcare; Chantal Laburte, MMV
External Scientiﬁc Advisory Committee (ESAC); David
McGibney, Chair of MMV ESAC; Andrew Humberstone,
Shire (formerly MMV at the time of the meeting); Julie
Lotharius, MMV; Joerg Moehrle, MMV; Claude Oeuvray,
MMV; Timothy Wells, MMV.
References
Alin MH, Ashton M, Kihamia CM, et al. (1996) Clinical efﬁcacy
and pharmacokinetics of artemisinin monotherapy and in
combination with meﬂoquine in patients with falciparum
malaria. British Journal of Clinical Pharmacology 41, 587–592.
Apt A & Kramnik I (2009) Man and mouse TB: contradictions
and solutions. Tuberculosis (Edinb) 89, 195–198.
Arnold L, Tyagi RK, Meija P, et al. (2011) Further improvements
of the P. falciparum humanized mouse model. PLoS One 6,
e18045.
Baird JK (2011) Resistance to chloroquine unhinges vivax malaria
therapeutics. Antimicrobial Agents and Chemotherapy 55,
1827–1830.
Bell A (2005) Antimalarial drug synergism and antagonism:
mechanistic and clinical signiﬁcance. FEMS Microbiology
Letters 253, 171–184.
Carneiro I, Roca-Feltrer A, Grifﬁn JT, et al. (2010) Age-patterns of
malaria vary with severity, transmission intensity and season-
ality in sub-Saharan Africa: a systematic review and pooled
analysis. PLoS One 5, e8988.
Co EM, Dennull RA, Reinbold DD, et al. (2009) Assessment of
malaria in vitro drug combination screening and mixed-strain
infections using the malaria Sybr green I-based ﬂuorescence
assay. Antimicrobial Agents and Chemotherapy 53, 2557–2563.
Galappaththy GN, Omari AA & Tharyan P (2007) Primaquine
for preventing relapses in people with Plasmodium vivax
malaria. Cochrane Database of Systematic Reviews (1),
CD004389.
Giao PT, Binh TQ, Kager PA, et al. (2001) Artemisinin for treat-
ment of uncomplicated falciparum malaria: is there a place for
Tropical Medicine and International Health volume 17 no 4 pp 409–413 april 2012
S. Duparc et al. Optimal dose for new malaria therapy
412 ª 2012 Blackwell Publishing Ltdmonotherapy? The American Journal of Tropical Medicine
and Hygiene 65, 690–695.
Langhorne J, Buffet P, Galinski M, et al. (2011) The relevance of
non-human primate and rodent malaria models for humans.
Malaria Journal 10, 23.
Mulenga M, Malunga P, Bennett S, et al. (2006) Folic acid treat-
ment of Zambian children with moderate to severe malaria
anemia. The American Journal of Tropical Medicine and
Hygiene 74, 986–990.
Myers R, Montgomery D & Anderson-Cook C (2009) Response
Surface Methodology: Process and Product Optimization Using
Designed Experiments. John Wiley & Sons, Hoboken, NJ.
Noedl H, Wongsrichanalai C & Wernsdorfer WH (2003) Malaria
drug-sensitivity testing: new assays, new perspectives. Trends
in Parasitology 19, 175–181.
Noedl H, Se Y, Schaecher K, et al. (2008) Evidence of artemisinin-
resistant malaria in western Cambodia. The New England
Journal of Medicine 359, 2619–2620.
Pool JL, Cushman WC, Saini RK, et al. (1997) Use of the factorial
design and quadratic response surface models to evaluate the
fosinopril and hydrochlorothiazide combination therapy in
hypertension. American Journal of Hypertension 10, 117–123.
Roll Back Malaria (2001) The Use of Antimalarial Drugs: Report
of an Informal Consultation. World Health Organization,
Geneva. http://www.rbm.who.int/cmc_upload/0/000/014/923/
am_toc.htm#toc. Accessed 8⁄4⁄2011.
The malERA Consultative Group on Drugs (2011) A research
agenda for malaria eradication: drugs. PLoS Med 8,
e1000402.
Wein S, Maynadier M, Tran Van Ba C, et al. (2010) Reliability
of antimalarial sensitivity tests depends on drug mecha-
nisms of action. Journal of Clinical Microbiology 48,
1651–1660.
White NJ (2010) Artemisinin resistance – the clock is ticking.
Lancet 376, 2051–2052.
Wootton DG, Opara H, Biagini GA, et al. (2008) Open-label
comparative clinical study of chlorproguanil-dapsone ﬁxed dose
combination (Lapdap ) alone or with three different doses of
artesunate for uncomplicated Plasmodium falciparum malaria.
PLoS One 3, e1779.
World Health Organization (2010) Global Report on Antimalarial
Drug Efﬁcacy and Drug Resistance: 2000–2010. World Health
Organization, Geneva. http://whqlibdoc.who.int/publications/
2010/9789241500470_eng.pdf. Accessed 20⁄3⁄2011.
World Health Organization (2011) Global Plan for Artemisinin
Resistance Containment (GPARC). World Health Organiza-
tion, Geneva. http://www.who.int/malaria/publications/atoz/
artemisinin_resistance_containment_2011.pdf. Accessed
20⁄3⁄2011.
Zhuang DM & Li JY (2011) A few specialized issues that should
be focused on anti-HIV drug evaluation in vitro. Virologica
Sinica 25, 301–306.
Corresponding Author S. Duparc, Medicines for Malaria Venture, International Center Cointrin, 20 Route de Pre ´-Bois, 1215
Geneva 15, Switzerland. Tel.: +41 (0)22 799 4070; Fax: +41 (0)22 799 4061; E-mail: duparcs@mmv.org
Tropical Medicine and International Health volume 17 no 4 pp 409–413 april 2012
S. Duparc et al. Optimal dose for new malaria therapy
ª 2012 Blackwell Publishing Ltd 413